Please provide your email address to receive an email when new articles are posted on . IHL-42X is a combination pharmacotherapy for OSA. IHL-42X groups had greater decreases in disease severity vs.
A study identified three existing drugs that target key genes implicated in a rare infant leukemia. The drugs showed anti-leukemic effects in mice and suggest repurposing strategies as alternatives to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results